New CEOs at eGenesis, Fore and Cerevance
Plus Ramanan joins Turnstone as CFO, updates from Camp4, ImmPact, Akoya and more
eGenesis Inc. hired Michael Curtis as CEO, succeeding Paul Sekhri, who remains on the board. Curtis joined the company in 2020 as president of R&D. Before eGenesis, Curtis was president and head of R&D at Cadent Therapeutics Inc., which was acquired by Novartis AG (SIX:NOVN; NYSE:NVS). eGenesis, which is using its genome engineering platform to make human compatible organs and cells, said the change reflect its portfolio’s advancement toward the clinic.
Oncology company Fore Biotherapeutics Inc. named Matthew Ros as CEO and a board member. Ros, a 17-year veteran of Bristol Myers Squibb Co. (NYSE:BMY), was EVP and chief strategy and business officer at Epizyme Inc. (NASDAQ:EPZM), and COO and global head of oncology business unit at Sanofi-Genzyme...